betaxolol has been researched along with quinoxalines in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (17.39) | 18.2507 |
| 2000's | 14 (60.87) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, KS; Nordlund, JR; Ordman, J; Pasquale, LR; Robin, AL; Rudikoff, MT; Walt, J | 1 |
| Serle, JB | 1 |
| Kleven, MS; Koek, W | 1 |
| Greenfield, DS; Liebmann, JM; Ritch, R | 1 |
| Goldberg, I; Javitt, J | 1 |
| Cantor, LB; Flartey, K; Hoop, J; Katz, LJ | 1 |
| An, P; Magar, R; Marchetti, A; Nichol, M | 1 |
| Grehn, F | 1 |
| Baldridge, WH; Baptiste, DC; Chauhan, BC; Hartwick, AT; Jollimore, CA; Kelly, ME; Tremblay, F | 1 |
| Holló, G; Kóthy, P | 1 |
| Bunce, C; Garway-Heath, DF; Hitchings, RA; Indar, A; Poinoosawmy, D | 1 |
| Fong, JC; Hong, SJ; Wang, HZ; Wu, KY | 1 |
| Assalian, A; Castilloux, AM; Houde, M; LeLorier, J; Tingey, D | 1 |
| Asagidag, A; Celik, A; Ermis, SS; Inan, UU; Onrat, E; Orman, A; Ozturk, F; Yucel, A | 1 |
| Ignat, F | 1 |
| Koob, GF; Lekic, DM; Mandyam, CD; Wee, S | 1 |
| Karczewicz, D; Kuprjanowicz, L | 1 |
| Cai, JP; Cheng, JW; Wei, RL | 1 |
| Clark, AF; Millar, JC; Pang, IH | 1 |
| Abdlseaed, AA; Abeysinghe, SS; Kelly, S; Montgomery, DM; Rahman, MQ; Roskell, NS; Shannon, PR | 1 |
| Cho, HK; Kee, C | 1 |
| Fukuchi, T | 1 |
| Chi, W; Li, A; Wang, S; Zhu, X | 1 |
4 review(s) available for betaxolol and quinoxalines
| Article | Year |
|---|---|
Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Betaxolol; Brimonidine Tartrate; Clinical Trials as Topic; Dose-Response Relationship, Drug; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Timolol; Trabeculectomy | 1997 |
Clinical and economic impact of new trends in glaucoma treatment.
Topics: Adult; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Cost-Benefit Analysis; Critical Pathways; Decision Trees; Female; Glaucoma, Open-Angle; Humans; Male; Quinoxalines; Randomized Controlled Trials as Topic; Trabeculectomy | 2001 |
[Neuroprotection in glaucoma].
Topics: Betaxolol; Brimonidine Tartrate; Disease Progression; Glaucoma; Guanidines; Humans; Memantine; Neuroprotective Agents; Quinoxalines; Sulfonamides; Thiophenes | 2007 |
Meta-analysis of medical intervention for normal tension glaucoma.
Topics: Aged; Amides; Antihypertensive Agents; Betaxolol; Bimatoprost; Brimonidine Tartrate; Cloprostenol; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Prostaglandins F, Synthetic; Quinoxalines; Randomized Controlled Trials as Topic; Sulfonamides; Thiazines; Thiophenes; Timolol; Tonometry, Ocular; Travoprost | 2009 |
8 trial(s) available for betaxolol and quinoxalines
| Article | Year |
|---|---|
The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine.
Topics: Adrenergic alpha-Agonists; Adult; Betaxolol; Brimonidine Tartrate; Cross-Over Studies; Double-Blind Method; Exercise Test; Hemodynamics; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypotension; Ophthalmic Solutions; Quinoxalines; Respiration; Timolol | 1995 |
A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Drug Administration Schedule; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Safety; Treatment Outcome | 1996 |
Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Betaxolol; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Drug Evaluation; Female; Glaucoma, Open-Angle; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quality of Life; Quinoxalines; Safety; Suspensions; Treatment Outcome | 2000 |
Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Betaxolol; Brimonidine Tartrate; Female; Humans; Intraocular Pressure; Male; Middle Aged; Multicenter Studies as Topic; Ocular Hypertension; Quality of Life; Quinoxalines; Treatment Outcome | 2001 |
Clinical and economic impact of new trends in glaucoma treatment.
Topics: Adult; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Cost-Benefit Analysis; Critical Pathways; Decision Trees; Female; Glaucoma, Open-Angle; Humans; Male; Quinoxalines; Randomized Controlled Trials as Topic; Trabeculectomy | 2001 |
Does glaucoma medication influence the diameter of the retinal arteriole in the human eye? (A pilot study using the retinal vessel analyser).
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Arterioles; Betaxolol; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Glaucoma; Humans; Latanoprost; Middle Aged; Ophthalmology; Pilot Projects; Prostaglandins F, Synthetic; Quinoxalines; Retinal Artery; Sulfonamides; Thiazines; Timolol | 2001 |
The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol.
Topics: Administration, Topical; Adult; Amides; Betaxolol; Bimatoprost; Brimonidine Tartrate; Cardiovascular System; Cloprostenol; Cross-Over Studies; Double-Blind Method; Eye; Humans; Intraocular Pressure; Lipids; Male; Ocular Hypotension; Prospective Studies; Pulmonary Circulation; Quinoxalines; Regional Blood Flow; Travoprost | 2004 |
Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension.
Topics: Aged; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Drug Administration Schedule; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ocular Hypotension; Quinoxalines; Tonometry, Ocular; Treatment Outcome | 2013 |
12 other study(ies) available for betaxolol and quinoxalines
| Article | Year |
|---|---|
Discriminative stimulus properties of cocaine: enhancement by beta-adrenergic receptor antagonists.
Topics: Adrenergic beta-Antagonists; Animals; Benzofurans; Betaxolol; Brimonidine Tartrate; Cocaine; Discrimination Learning; Discrimination, Psychological; Drug Synergism; Imidazoles; Male; Nadolol; Narcotics; Propanolamines; Propranolol; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Thiophenes | 1997 |
[Prospects for neuroprotective glaucoma therapy].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis; Betaxolol; Brain-Derived Neurotrophic Factor; Brimonidine Tartrate; Calcium Channel Blockers; Disease Models, Animal; Dopamine Agents; Glaucoma; Glaucoma, Open-Angle; Haplorhini; Humans; Memantine; Neuroprotective Agents; Nimodipine; Nitric Oxide Synthase; Quinoxalines; Receptors, N-Methyl-D-Aspartate | 2001 |
Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Betaxolol; Brimonidine Tartrate; Calcium; Cell Culture Techniques; Cell Survival; Dose-Response Relationship, Drug; Fura-2; Glutamic Acid; Metoprolol; N-Methylaspartate; Neuroglia; Neuroprotective Agents; Quinoxalines; Rats; Rats, Long-Evans; Retina; Retinal Ganglion Cells; Timolol | 2002 |
Effect of treatment by medicine or surgery on intraocular pressure and pulsatile ocular blood flow in normal-pressure glaucoma.
Topics: Administration, Topical; Aged; Antihypertensive Agents; Betaxolol; Blood Flow Velocity; Brimonidine Tartrate; Eye; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Ophthalmic Solutions; Prostaglandins F, Synthetic; Pulsatile Flow; Quinoxalines; Retrospective Studies; Tonometry, Ocular; Trabeculectomy | 2002 |
Effects of commercial antiglaucoma drugs to glutamate-induced [Ca2+)]i increase in cultured neuroblastoma cells.
Topics: Animals; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Calcium; Carteolol; Cell Death; Dose-Response Relationship, Drug; Epinephrine; Glaucoma; Glutamic Acid; Latanoprost; Mice; Neuroblastoma; Neurons; Neuroprotective Agents; Pilocarpine; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Thiophenes; Timolol; Tumor Cells, Cultured | 2003 |
Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Contraindications; Databases, Factual; Drug Prescriptions; Female; Glaucoma; Humans; Latanoprost; Male; Middle Aged; National Health Programs; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quebec; Quinoxalines; Retrospective Studies; Sulfonamides; Thiophenes; Timolol | 2003 |
[Neuroprotection and vasoprotection in glaucoma].
Topics: Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Carteolol; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Neuroprotective Agents; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Treatment Outcome | 2004 |
Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Betaxolol; Brain Chemistry; Brimonidine Tartrate; Cocaine-Related Disorders; Conditioning, Operant; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Immunohistochemistry; Male; Motivation; Prazosin; Quinoxalines; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Self Administration; Septal Nuclei | 2008 |
Assessment of aqueous humor dynamics in the mouse by a novel method of constant-flow infusion.
Topics: Animals; Antihypertensive Agents; Aqueous Humor; Betaxolol; Brimonidine Tartrate; Coloring Agents; Dextrans; Fluorescein-5-isothiocyanate; Intraocular Pressure; Latanoprost; Male; Manometry; Mice; Mice, Inbred BALB C; Prostaglandins F, Synthetic; Quinoxalines; Sclera; Tonometry, Ocular; Trabecular Meshwork; Uvea; Venous Pressure | 2011 |
Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database.
Topics: Algorithms; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Clinical Protocols; Databases, Factual; Drug Utilization; Female; Glaucoma; Humans; Male; Ocular Hypertension; Quinoxalines; Scotland; Timolol | 2011 |
Comparison of the progression rates of the superior, inferior, and both hemifield defects in normal-tension glaucoma patients.
Topics: Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Cohort Studies; Disease Progression; Female; Humans; Intraocular Pressure; Latanoprost; Low Tension Glaucoma; Male; Middle Aged; Nerve Fibers; Prostaglandins F, Synthetic; Quinoxalines; Retinal Ganglion Cells; Retrospective Studies; Tonometry, Ocular; Vision Disorders; Visual Field Tests; Visual Fields | 2012 |
[Current trend of glaucoma medication with various eye drops].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Glaucoma; Humans; Latanoprost; Neuroprotective Agents; Ophthalmic Solutions; Ophthalmology; Prostaglandins; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 2013 |